A detailed history of Ameritas Investment Partners, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 24,805 shares of IOVA stock, worth $201,912. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,805
Previous 24,805 -0.0%
Holding current value
$201,912
Previous $198,000 17.17%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$7.78 - $14.19 $14,128 - $25,769
1,816 Added 7.9%
24,805 $198,000
Q3 2023

Nov 13, 2023

BUY
$4.44 - $8.79 $25,791 - $51,061
5,809 Added 33.81%
22,989 $104,000
Q2 2023

Aug 11, 2023

BUY
$5.36 - $9.06 $31,473 - $53,200
5,872 Added 51.93%
17,180 $120,000
Q2 2022

Aug 12, 2022

BUY
$6.38 - $18.33 $72,145 - $207,275
11,308 New
11,308 $124,000
Q2 2020

Aug 05, 2020

SELL
$27.21 - $41.0 $278,140 - $419,102
-10,222 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$19.54 - $38.85 $2,872 - $5,710
147 Added 1.46%
10,222 $306,000
Q4 2019

Feb 13, 2020

BUY
$17.95 - $29.41 $5,528 - $9,058
308 Added 3.15%
10,075 $279,000
Q2 2019

Aug 14, 2019

BUY
$9.78 - $24.52 $9,868 - $24,740
1,009 Added 11.52%
9,767 $239,000
Q4 2018

Feb 12, 2019

BUY
$7.51 - $11.93 $13,142 - $20,877
1,750 Added 24.97%
8,758 $78,000
Q2 2018

Aug 13, 2018

BUY
$12.45 - $16.95 $9,773 - $13,305
785 Added 12.61%
7,008 $90,000
Q1 2018

May 15, 2018

BUY
$8.1 - $19.5 $13,219 - $31,824
1,632 Added 35.55%
6,223 $105,000
Q2 2017

Aug 15, 2017

BUY
N/A
4,591
4,591 $34,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.